Loading...
•
Sep 30, 2021
Arcutis Q3 2021 Earnings Report
Arcutis reported results for the third quarter of 2021 and provided a business update.
Key Takeaways
Arcutis Biotherapeutics reported a net loss of $57.0 million for the quarter ended September 30, 2021. The company's cash, cash equivalents, and marketable securities totaled $368.8 million as of September 30, 2021, expected to fund operations well into 2023. The company submitted an NDA for roflumilast cream for plaque psoriasis and initiated a Phase 3 trial for roflumilast foam in scalp and body psoriasis.
Submitted NDA for roflumilast cream for plaque psoriasis.
Initiated Phase 3 trial of roflumilast foam in scalp and body psoriasis.
Continued enrollment in Phase 3 trials for roflumilast cream in atopic dermatitis and roflumilast foam in seborrheic dermatitis.
Expanded patent portfolio with a pharmacokinetics patent for topical roflumilast.
Arcutis
Arcutis
Forward Guidance
Arcutis anticipates a transformative 2022, with a potential launch in plaque psoriasis and three additional Phase 3 clinical data readouts expected.